145 related articles for article (PubMed ID: 15752377)
1. Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis.
van Kan HJ; Groeneveld GJ; Kalmijn S; Spieksma M; van den Berg LH; Guchelaar HJ
Br J Clin Pharmacol; 2005 Mar; 59(3):310-3. PubMed ID: 15752377
[TBL] [Abstract][Full Text] [Related]
2. Riluzole metabolism and CYP1A1/2 polymorphisms in patients with ALS.
Ajroud-Driss S; Saeed M; Khan H; Siddique N; Hung WY; Sufit R; Heller S; Armstrong J; Casey P; Siddique T; Lukas TJ
Amyotroph Lateral Scler; 2007 Oct; 8(5):305-9. PubMed ID: 17852022
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of riluzole: evidence for glucuronidation as a major metabolic pathway not associated with UGT1A1 genotype.
van Kan HJ; van den Berg LH; Groeneveld GJ; van der Straaten RJ; van Vught PW; Lie-A-Huen L; Guchelaar HJ
Biopharm Drug Dispos; 2008 Apr; 29(3):139-44. PubMed ID: 18098330
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis.
Bruno R; Vivier N; Montay G; Le Liboux A; Powe LK; Delumeau JC; Rhodes GR
Clin Pharmacol Ther; 1997 Nov; 62(5):518-26. PubMed ID: 9390108
[TBL] [Abstract][Full Text] [Related]
5. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
[TBL] [Abstract][Full Text] [Related]
6. An association study of riluzole serum concentration and survival and disease progression in patients with ALS.
Groeneveld GJ; van Kan HJ; Lie-A-Huen L; Guchelaar HJ; van den Berg LH
Clin Pharmacol Ther; 2008 May; 83(5):718-22. PubMed ID: 17898704
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics.
Perera V; Gross AS; Xu H; McLachlan AJ
J Pharm Pharmacol; 2011 Sep; 63(9):1161-8. PubMed ID: 21827488
[TBL] [Abstract][Full Text] [Related]
8. Riluzole 5 mg/mL oral suspension: for optimized drug delivery in amyotrophic lateral sclerosis.
Dyer AM; Smith A
Drug Des Devel Ther; 2017; 11():59-64. PubMed ID: 28053507
[TBL] [Abstract][Full Text] [Related]
9. Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study.
Härtter S; Ursing C; Morita S; Tybring G; von Bahr C; Christensen M; Röjdmark S; Bertilsson L
Clin Pharmacol Ther; 2001 Jul; 70(1):10-6. PubMed ID: 11452239
[TBL] [Abstract][Full Text] [Related]
10. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking.
Faber MS; Fuhr U
Clin Pharmacol Ther; 2004 Aug; 76(2):178-84. PubMed ID: 15289794
[TBL] [Abstract][Full Text] [Related]
11. Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics.
Dash RP; Babu RJ; Srinivas NR
Clin Pharmacokinet; 2018 Nov; 57(11):1385-1398. PubMed ID: 29682695
[TBL] [Abstract][Full Text] [Related]
12. An outcome study of riluzole in amyotrophic lateral sclerosis--a population-based study in Ireland, 1996-2000.
Traynor BJ; Alexander M; Corr B; Frost E; Hardiman O
J Neurol; 2003 Apr; 250(4):473-9. PubMed ID: 12700914
[TBL] [Abstract][Full Text] [Related]
13. [Liver Injury Risk Factors in Amyotrophic Lateral Sclerosis Patients Treated with Riluzole].
Kawano C; Isozaki Y; Nakagawa A; Hirayama T; Nishiyama K; Kuroyama M
Yakugaku Zasshi; 2020; 140(7):923-928. PubMed ID: 32612057
[TBL] [Abstract][Full Text] [Related]
14. The ALS/MND prevalence in Sweden estimated by riluzole sales statistics.
Nygren I; Antonova K; Mattsson P; Askmark H
Acta Neurol Scand; 2005 Mar; 111(3):180-4. PubMed ID: 15691287
[TBL] [Abstract][Full Text] [Related]
15. A Phase 1 Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects.
Thai C; Tayo B; Critchley D
Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1279-1289. PubMed ID: 33951339
[TBL] [Abstract][Full Text] [Related]
16. Inter- and intraindividual variability of riluzole serum concentrations in patients with ALS.
Groeneveld GJ; van Kan HJ; Toraño JS; Veldink JH; Guchelaar HJ; Wokke JH; van den Berg LH
J Neurol Sci; 2001 Oct; 191(1-2):121-5. PubMed ID: 11677002
[TBL] [Abstract][Full Text] [Related]
17. Validation of urine caffeine metabolite ratios with use of stable isotope-labeled caffeine clearance.
Denaro CP; Wilson M; Jacob P; Benowitz NL
Clin Pharmacol Ther; 1996 Mar; 59(3):284-96. PubMed ID: 8653991
[TBL] [Abstract][Full Text] [Related]
18. Paraxanthine/Caffeine Concentration Ratios in Hair: An Alternative for Plasma-Based Phenotyping of Cytochrome P450 1A2?
De Kesel PM; Lambert WE; Stove CP
Clin Pharmacokinet; 2015 Jul; 54(7):771-81. PubMed ID: 25603821
[TBL] [Abstract][Full Text] [Related]
19. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2.
Kinzig-Schippers M; Fuhr U; Zaigler M; Dammeyer J; Rüsing G; Labedzki A; Bulitta J; Sörgel F
Clin Pharmacol Ther; 1999 Mar; 65(3):262-74. PubMed ID: 10096258
[TBL] [Abstract][Full Text] [Related]
20. Effects of riluzole on cortical excitability in patients with amyotrophic lateral sclerosis.
Stefan K; Kunesch E; Benecke R; Classen J
Ann Neurol; 2001 Apr; 49(4):536-9. PubMed ID: 11310635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
